Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ultragenyx Pharmaceutical (RARE) Invested Capital (2016 - 2025)

Historic Invested Capital for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Q3 2025 value amounting to $9.2 million.

  • Ultragenyx Pharmaceutical's Invested Capital fell 9735.92% to $9.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.2 million, marking a year-over-year decrease of 9735.92%. This contributed to the annual value of $255.3 million for FY2024, which is 730.43% down from last year.
  • As of Q3 2025, Ultragenyx Pharmaceutical's Invested Capital stood at $9.2 million, which was down 9735.92% from $151.3 million recorded in Q2 2025.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Invested Capital peaked at $1.1 billion during Q1 2021, and registered a low of $9.2 million during Q3 2025.
  • Its 5-year average for Invested Capital is $437.6 million, with a median of $346.8 million in 2024.
  • Per our database at Business Quant, Ultragenyx Pharmaceutical's Invested Capital skyrocketed by 99360.85% in 2024 and then crashed by 9735.92% in 2025.
  • Quarter analysis of 5 years shows Ultragenyx Pharmaceutical's Invested Capital stood at $922.6 million in 2021, then tumbled by 61.79% to $352.5 million in 2022, then fell by 21.87% to $275.4 million in 2023, then dropped by 7.3% to $255.3 million in 2024, then tumbled by 96.41% to $9.2 million in 2025.
  • Its Invested Capital stands at $9.2 million for Q3 2025, versus $151.3 million for Q2 2025 and $144.2 million for Q1 2025.